STOCK TITAN

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Nuwellis (NUWE) has successfully regained compliance with Nasdaq's listing requirements, including both the minimum bid price and stockholders' equity requirements. The company will continue trading on the Nasdaq Capital Market under 'NUWE'. This achievement follows strategic financial moves including raising $5.1 million in gross proceeds through warrant exercises and a warrant inducement transaction in November. The company implemented a 1:35 reverse stock split on June 26, 2024, and has improved its balance sheet by raising new equity and reducing liabilities. Nuwellis now exceeds Nasdaq's stockholders' equity requirement of $2.5 million. The company will be subject to a mandatory panel monitor for one year from December 17, 2024.

Nuwellis (NUWE) ha riacquistato con successo la conformità ai requisiti di quotazione del Nasdaq, inclusi sia il prezzo minimo delle azioni che i requisiti di patrimonio netto degli azionisti. L'azienda continuerà a trattare sul Nasdaq Capital Market sotto 'NUWE'. Questo successo segue manovre finanziarie strategiche tra cui il reperimento di 5,1 milioni di dollari in proventi lordi attraverso l'esercizio di warrant e una transazione di inducement di warrant a novembre. L'azienda ha attuato un frazionamento azionario inverso 1:35 il 26 giugno 2024 e ha migliorato il proprio bilancio raccogliendo nuovo capitale e riducendo le passività. Nuwellis ora supera il requisito di patrimonio netto degli azionisti del Nasdaq di 2,5 milioni di dollari. L'azienda sarà soggetta a un monitoraggio obbligatorio da parte di un pannello per un anno a partire dal 17 dicembre 2024.

Nuwellis (NUWE) ha recuperado con éxito el cumplimiento de los requisitos de cotización de Nasdaq, incluyendo tanto el precio mínimo de la acción como los requisitos de patrimonio neto de los accionistas. La empresa continuará cotizando en el Nasdaq Capital Market bajo 'NUWE'. Este logro sigue a movimientos financieros estratégicos que incluyen recaudar 5,1 millones de dólares en ingresos brutos a través del ejercicio de warrants y una transacción de inducement de warrants en noviembre. La empresa implementó un split de acciones inverso 1:35 el 26 de junio de 2024 y ha mejorado su balance general al recaudar nuevo capital y reducir pasivos. Nuwellis ahora supera el requisito de patrimonio neto de accionistas de Nasdaq de 2,5 millones de dólares. La empresa estará sujeta a un monitor de panel obligatorio durante un año a partir del 17 de diciembre de 2024.

누웰리스 (NUWE)는 나스닥 상장 요건을 성공적으로 회복했으며, 최소 매물가 및 주주 자본 요건을 포함합니다. 이 회사는 'NUWE'라는 이름으로 나스닥 자본 시장에서 계속 거래할 것입니다. 이 성과는 510만 달러를 모금하는 등 전략적인 재정 조치에 이어 이루어졌으며, 이는 보증서 행사와 11월 보증서 유인 거래를 통해 이루어졌습니다. 회사는 2024년 6월 26일에 1:35 비율의 액면 분할을 시행했으며, 새로운 자본을 조달하고 부채를 줄여 재무 상태를 개선했습니다. 누웰리스는 이제 나스닥의 주주 자본 요건인 250만 달러를 초과합니다. 이 회사는 2024년 12월 17일부터 1년간 의무적인 패널 모니터링을 받게 됩니다.

Nuwellis (NUWE) a réussi à retrouver sa conformité avec les exigences de cotation de Nasdaq, y compris à la fois le prix minimum des offres et les exigences de fonds propres des actionnaires. L'entreprise continuera à être cotée sur le Nasdaq Capital Market sous 'NUWE'. Ce succès fait suite à des mouvements financiers stratégiques, notamment la levée de 5,1 millions de dollars en produits bruts grâce à l'exercice de bons de souscription et une transaction d'incitation de bons de souscription en novembre. L'entreprise a mis en œuvre un fractionnement d'actions inversé de 1:35 le 26 juin 2024 et a amélioré son bilan en levant de nouveaux capitaux et en réduisant ses passifs. Nuwellis dépasse désormais l'exigence de fonds propres des actionnaires de Nasdaq de 2,5 millions de dollars. L'entreprise sera soumise à une surveillance obligatoire par un panel pendant un an à partir du 17 décembre 2024.

Nuwellis (NUWE) hat erfolgreich die Anforderungen zur Einhaltung der Nasdaq-Listung wiederhergestellt, einschließlich der Mindestkurse für Aktien und der Eigenkapitalanforderungen der Aktionäre. Das Unternehmen wird unter 'NUWE' weiterhin am Nasdaq Capital Market gehandelt. Dieser Erfolg folgt auf strategische finanzielle Maßnahmen, einschließlich der Beschaffung von 5,1 Millionen Dollar an Bruttoerlösen durch die Ausübung von Warrants und eine Transaktion zur Anwerbung von Warrants im November. Das Unternehmen führte am 26. Juni 2024 einen 1:35 Aktiensplit durch und verbesserte seine Bilanz durch die Beschaffung von neuem Eigenkapital und die Reduzierung von Verbindlichkeiten. Nuwellis erfüllt nun die Eigenkapitalanforderung von Nasdaq für Aktionäre in Höhe von 2,5 Millionen Dollar. Das Unternehmen unterliegt ab dem 17. Dezember 2024 für ein Jahr der Überwachung durch ein obligatorisches Panel.

Positive
  • Regained compliance with Nasdaq listing requirements
  • Raised $5.1 million in gross proceeds from warrant exercises
  • Successfully exceeded $2.5 million stockholders' equity requirement
  • Improved balance sheet through liability reduction
Negative
  • Required 1:35 reverse stock split to meet listing requirements
  • Subject to mandatory Nasdaq panel monitoring for one year

Insights

<p>The regaining of Nasdaq compliance marks a important turning point for Nuwellis. The company has successfully addressed two critical listing requirements: the <b>minimum bid price</b> and <b>stockholders' equity requirement of <money>$2.5 million</money></b>. Through strategic financial maneuvers, including a <b>1:35 reverse stock split</b> and raising <money>$5.1 million</money> in gross proceeds, the company has strengthened its balance sheet significantly.</p><p>The mandatory panel monitor period through December 2024 indicates ongoing scrutiny, but the company's ability to maintain compliance will be strengthened by its improved equity position. For a micro-cap company with a market cap of just <money>$4.37 million</money>, this compliance achievement is particularly notable as it removes an immediate existential threat and provides a more stable foundation for business operations.</p><p>Think of this like a company getting its credit score back above the minimum threshold - while it doesn't guarantee future success, it removes significant restrictions and opens up more opportunities for growth and investment.</p>

MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq’s stockholders’ equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Common Stock will continue to trade on The Nasdaq Capital Market tier of Nasdaq under the symbol "NUWE".

This confirmation follows the Company’s successful efforts to improve its balance sheet by raising new equity, reducing outstanding liabilities, and reclassifying certain prior warrant liabilities as equity. As a result, Nuwellis now exceeds Nasdaq’s stockholders' Equity Requirement of at least $2.5 million, which was previously reported on our Form 10-Q for the period ending September 30, 2024.

Nestor Jaramillo, President and CEO of Nuwellis, said: "We are pleased to receive Nasdaq’s written notification confirming Nuwellis has regained compliance with both the minimum stockholders’ Equity Requirement and the Bid Price Requirement. Over the past few months, we have made significant strides in improving our balance sheet and expanding our business. This includes the successful raise of $5.1 million in gross proceeds from warrant exercises and through our recent warrant inducement transaction in November. In addition, we implemented a reverse stock split of 1:35 on June 26, 2024.”

As part of the compliance confirmation, Nuwellis will be subject to a mandatory panel monitor for a year from the date the letter was received, December 17, 2024.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the Company’s ability to maintain the continued listing of the Company’s securities on Nasdaq. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

CONTACTS

Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com


FAQ

How did Nuwellis (NUWE) regain Nasdaq compliance in December 2024?

Nuwellis regained compliance through multiple actions including raising $5.1 million in gross proceeds, implementing a 1:35 reverse stock split, reducing liabilities, and exceeding the $2.5 million stockholders' equity requirement.

What was the ratio of NUWE's reverse stock split in June 2024?

Nuwellis implemented a 1:35 reverse stock split on June 26, 2024.

How much capital did NUWE raise through warrant exercises in 2024?

Nuwellis raised $5.1 million in gross proceeds through warrant exercises and a warrant inducement transaction in November 2024.

What are the monitoring requirements for NUWE after regaining Nasdaq compliance?

Nuwellis will be subject to a mandatory panel monitor for one year from December 17, 2024.

What is the minimum stockholders' equity requirement NUWE needed to meet for Nasdaq?

Nuwellis needed to meet a minimum stockholders' equity requirement of $2.5 million, which they successfully exceeded.

Nuwellis, Inc.

NASDAQ:NUWE

NUWE Rankings

NUWE Latest News

NUWE Stock Data

4.37M
4.34M
1.6%
1.46%
17.27%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
EDEN PRAIRIE